WO2019000149A1 - Sirna of human programmed death-ligand 1 gene and use thereof - Google Patents
Sirna of human programmed death-ligand 1 gene and use thereof Download PDFInfo
- Publication number
- WO2019000149A1 WO2019000149A1 PCT/CN2017/089929 CN2017089929W WO2019000149A1 WO 2019000149 A1 WO2019000149 A1 WO 2019000149A1 CN 2017089929 W CN2017089929 W CN 2017089929W WO 2019000149 A1 WO2019000149 A1 WO 2019000149A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- gene
- sirna
- sequence
- ligand
- programmed death
- Prior art date
Links
- 108020004459 Small interfering RNA Proteins 0.000 title description 10
- 101001117317 Homo sapiens Programmed cell death 1 ligand 1 Proteins 0.000 title description 6
- 108010074708 B7-H1 Antigen Proteins 0.000 claims abstract description 18
- 230000014509 gene expression Effects 0.000 claims abstract description 12
- 238000012228 RNA interference-mediated gene silencing Methods 0.000 claims abstract description 7
- 230000009368 gene silencing by RNA Effects 0.000 claims abstract description 7
- 201000010099 disease Diseases 0.000 claims abstract description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 4
- 239000003814 drug Substances 0.000 claims abstract description 4
- 239000012634 fragment Substances 0.000 claims abstract 4
- 230000002159 abnormal effect Effects 0.000 claims abstract 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 3
- 230000000692 anti-sense effect Effects 0.000 claims description 3
- 229940079593 drug Drugs 0.000 abstract 1
- 102000008096 B7-H1 Antigen Human genes 0.000 description 12
- 210000004027 cell Anatomy 0.000 description 12
- 239000004055 small Interfering RNA Substances 0.000 description 9
- 206010028980 Neoplasm Diseases 0.000 description 6
- 238000000034 method Methods 0.000 description 5
- 238000001514 detection method Methods 0.000 description 4
- 108020004999 messenger RNA Proteins 0.000 description 4
- 238000003753 real-time PCR Methods 0.000 description 4
- 210000001744 T-lymphocyte Anatomy 0.000 description 3
- 230000000139 costimulatory effect Effects 0.000 description 3
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 238000001890 transfection Methods 0.000 description 3
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- 238000002123 RNA extraction Methods 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 230000017188 evasion or tolerance of host immune response Effects 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 238000010839 reverse transcription Methods 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 101710094000 Programmed cell death 1 ligand 1 Proteins 0.000 description 1
- 102100024216 Programmed cell death 1 ligand 1 Human genes 0.000 description 1
- 238000011530 RNeasy Mini Kit Methods 0.000 description 1
- 108091081021 Sense strand Proteins 0.000 description 1
- 108091081024 Start codon Proteins 0.000 description 1
- 230000006044 T cell activation Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
Definitions
- the present invention belongs to the field of molecular genetics, and more particularly to a siRN capable of inhibiting human programmed death ligand 1
- Non-small cell lung cancer is a common malignant tumor in the world, and its incidence is increasing year by year. Studying NSCLC tumor recurrence factors and tumor immune escape mechanisms has important theoretical significance and clinical application value. T lymphocytes are important effector cells that mediate tumor immune responses, and T cell activation requires TCR-mediated antigen-specific signaling and costimulatory molecule-mediated costimulatory signals.
- PD-L1 Programmed death ligand 1
- B7-H1 is a negative T cell costimulatory molecule in the B7 family
- PD-L1 inhibits proliferation of CD4 and CD8 T cells by binding to its receptor PD-1
- activation negative regulation of the body's immune response process, thereby mediating tumor immune escape, and promoting tumor growth
- the vector that inhibits the expression of the PD-L1 gene makes the related research not well developed.
- RNA interference RNA interference
- RNAi small interfering RNA
- siPDL1 sequence is as follows: [0007] Justice Chain: 5,- GCCGAAGUCAUCUGGACAA-3' (SEQ ID NO: 1)
- Antisense strand 5,- UUGUCCAGAUGACUUCGGC-3' (SEQ ID NO: 2).
- the siPDL1 provided by the present invention has the advantages of high interference efficiency, high and specific inhibition of PD-L1 gene expression, and can be used as a powerful tool for preparing a medicament for treating a PD-L1 gene expression-related disease. Brief description of the drawing
- FIG. 1 is a schematic diagram showing the results of quantitative PCR detection of PD-L1 gene expression levels after HepG2 cells transfected with siPDL1.
- HepG2 cells purchased from ATCC
- cultured in DMEM complete medium containing 10% fetal bovine serum
- plated 6-well plates at a ratio of 150,000 cells/well, and cultured at 37 ° C, 5% CO 2 for 18 h.
- Cell transfection was performed using the Lipofectamine 3000 Transfection Kit (Invitrogen) according to the product instructions.
- Transfected sputum, transfected A375 cells with lOO pmol siPDL1 the ratio of siRNA to liposome was 100 pmol: 10 ⁇ .
- Total RNA extraction Total RNA of PD-L1 cells normal and transfected with siPDL1 was extracted using the QIAGEN RNeasy Mini Kit.
- Reverse Transcription Reverse transcription was performed using FastQuant RT Super Mix.
- the siPDL1 provided by the present invention has the advantages of high interference efficiency, high and specific inhibition of PD-L1 gene expression, and can be used as a powerful tool for preparing a medicament for treating a PD-L1 gene expression-related disease.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Veterinary Medicine (AREA)
- Biotechnology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- General Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Disclosed are an RNA interference fragment and the use of same in the preparation of a drug for treating a disease associated with the abnormal expression of the PD-L1 gene.
Description
说明书 发明名称：一种人程序性死亡配体 1基因的 siRNA及其应用 技术领域 Description: A human programmed death ligand 1 gene siRNA and its application
[0001] 本发明属于分子遗传学领域， 尤其涉及一种能抑制人程序性死亡配体 1的 siRN [0001] The present invention belongs to the field of molecular genetics, and more particularly to a siRN capable of inhibiting human programmed death ligand 1
A及其应用。 A and its application.
背景技术 Background technique
[0002] 非小细胞肺癌 （non-small cell lung cancer, NSCLC) 是当前世界的常见恶性肿 瘤， 其发病率有逐年增加的趋势。 研究 NSCLC肿瘤复发因素及肿瘤免疫逃逸机 制， 具有重要的理论意义和临床应用价值。 T淋巴细胞是介导肿瘤免疫应答的重 要效应细胞， T细胞活化需要 TCR介导的抗原特异性信号和共刺激分子介导的共 刺激信号。 [0002] Non-small cell lung cancer (NSCLC) is a common malignant tumor in the world, and its incidence is increasing year by year. Studying NSCLC tumor recurrence factors and tumor immune escape mechanisms has important theoretical significance and clinical application value. T lymphocytes are important effector cells that mediate tumor immune responses, and T cell activation requires TCR-mediated antigen-specific signaling and costimulatory molecule-mediated costimulatory signals.
技术问题 technical problem
[0003] 程序性死亡配体 1 (PD-L1) /B7-H1是 B7家族中一个负性 T细胞共刺激分子， PD-L1通过与其受体 PD-1结合， 抑制 CD4和 CD8T细胞的增殖和活化， 负性调控 机体免疫应答过程， 从而介导肿瘤免疫逃逸， 促进肿瘤生长， 因此对 PD-L1在肿 瘤逃逸中作用的研究对于肿瘤的防治具有重要的作用， 但现有技术中缺乏特异 抑制 PD-L1基因表达的载体使得相关研究无法很好地幵展。 [0003] Programmed death ligand 1 (PD-L1) / B7-H1 is a negative T cell costimulatory molecule in the B7 family, PD-L1 inhibits proliferation of CD4 and CD8 T cells by binding to its receptor PD-1 And activation, negative regulation of the body's immune response process, thereby mediating tumor immune escape, and promoting tumor growth, so the study of the role of PD-L1 in tumor escape has an important role in the prevention and treatment of tumors, but the lack of specificity in the prior art The vector that inhibits the expression of the PD-L1 gene makes the related research not well developed.
[0004] RNA干扰（RNA interference, RNAi)现象最早是由 Jorgensen等在发现的， 它 是一种高效、 特异性强的基因阻断技术， 近年来发展迅速， 很快就成为功能基 因组研究的有力工具， 可高效、 特异地抑制人 PD-L1基因表达， 进而为其功能研 究打下基础。 [0004] The phenomenon of RNA interference (RNAi) was first discovered by Jorgensen et al. It is a highly efficient and specific gene blocking technology, which has developed rapidly in recent years and soon became a powerful functional genomics research. The tool can efficiently and specifically inhibit the expression of human PD-L1 gene, which lays a foundation for its functional research.
问题的解决方案 Problem solution
技术解决方案 Technical solution
[0005] 本发明的目的在于提供一种基于 RNAi技术的针对人 PD-L1基因 mRNA的小分子 干扰 RNA (siRNA) 。 [0005] It is an object of the present invention to provide a small interfering RNA (siRNA) targeting human PD-L1 gene mRNA based on RNAi technology.
[0006] 从 GenBank获得人 PD-L1基因的 cDNA序列， 根据 siRNA靶序列的基本原则， 针对其设计了一条 19 nt的 siRNA: siPDLl序列如下：
[0007] 正义链： 5，- GCCGAAGUCAUCUGGACAA-3' (SEQ ID NO: 1) [0006] The cDNA sequence of human PD-L1 gene was obtained from GenBank. According to the basic principle of siRNA target sequence, a 19 nt siRNA was designed: siPDL1 sequence is as follows: [0007] Justice Chain: 5,- GCCGAAGUCAUCUGGACAA-3' (SEQ ID NO: 1)
[0008] 反义链： 5，- UUGUCCAGAUGACUUCGGC-3' (SEQ ID NO: 2) 。 Antisense strand: 5,- UUGUCCAGAUGACUUCGGC-3' (SEQ ID NO: 2).
发明的有益效果 Advantageous effects of the invention
有益效果 Beneficial effect
[0009] 本发明提供的 siPDLl具有干扰效率高， 可高效、 特异地抑制 PD-L1基因表达的 优点， 可作为有力工具应用于制备治疗 PD-L1基因表达异常相关疾病的药物。 对附图的简要说明 [0009] The siPDL1 provided by the present invention has the advantages of high interference efficiency, high and specific inhibition of PD-L1 gene expression, and can be used as a powerful tool for preparing a medicament for treating a PD-L1 gene expression-related disease. Brief description of the drawing
附图说明 DRAWINGS
[0010] 图 1为 HepG2细胞转染 siPDLl后定量 PCR检测 PD-L1基因表达水平的结果示意图 实施该发明的最佳实施例 1 is a schematic diagram showing the results of quantitative PCR detection of PD-L1 gene expression levels after HepG2 cells transfected with siPDL1. BEST MODE FOR CARRYING OUT THE INVENTION
本发明的最佳实施方式 BEST MODE FOR CARRYING OUT THE INVENTION
[0011] 下面结合附图与具体实施例对本发明做进一步的说明。 以下实施例中所使用的 技术， 包括 PCR扩增与检测、 细胞转染、 RNA提取等分子生物学技术， 以及细 胞培养、 检测技术等， 除非特别说明， 均为本领域内的技术人员已知的常规技 术； 所使用的仪器设备、 试剂和细胞系等， 除非是本说明书特别注明， 均为一 般本领域的研究和技术人员可以通过公共途径获得的。 [0011] The present invention will be further described below in conjunction with the accompanying drawings and specific embodiments. The techniques used in the following examples, including molecular techniques such as PCR amplification and detection, cell transfection, RNA extraction, and cell culture, detection techniques, and the like, are known to those skilled in the art unless otherwise specified. Conventional techniques; apparatus, reagents, cell lines, and the like, unless otherwise specified in the specification, are generally available to those skilled in the art and are available in the public.
[0012] 实施例一靶向 PD-L1基因的 siRNA寡核苷酸序列的设计 [0012] Example 1 Design of siRNA Oligonucleotide Sequence Targeting PD-L1 Gene
[0013] 在 GenBank査找到 PD-L1的 mRNA全序列， 从 PD-L1基因起始密码子 AUG下游 幵始， 搜索 AA序列， 其 3'端相邻 19 nt序列作为候选靶点， 从中选择 GC含量在 40-50%的 siRNA序列， 经 BLAST同源性比对证实特异性后应用 RNA structure 4.4 软件对靶 mRNA序列的二级结构进行评估， 最后获得靶核苷酸序列 siPDLl , 其正 义链序列如 SEQ ID NO: 1， 反义链序列如 SEQ ID NO: 2所示。 [0013] Find the full sequence of PD-L1 mRNA in GenBank, search for the AA sequence from the downstream of the PD-L1 gene start codon AUG, and select the adjacent 19 nt sequence at the 3' end as a candidate target, and select GC from it. The siRNA sequence with 40-50% content was confirmed by BLAST homology alignment. The secondary structure of the target mRNA sequence was evaluated by RNA structure 4.4 software. Finally, the target nucleotide sequence siPDLl was obtained, and the sense strand sequence was obtained. As SEQ ID NO: 1, the antisense strand sequence is set forth in SEQ ID NO: 2.
[0014] 实施例二 siRNA转染 HepG2细胞。 Example 2 siRNA was transfected into HepG2 cells.
[0015] HepG2细胞 （购自 ATCC) ， 用 DMEM完全培养基 （含 10%胎牛血清） 培养， 按照 15万个 /孔的比例铺 6孔板， 于 37°C、 5% C02培养 18 h。 用 Lipofectamine 3000转染试剂盒（Invitrogen)进行细胞转染， 方法按照产品说明。
转染吋， 用 lOO pmol siPDLl转染 A375细胞， siRNA与脂质体比例为 100 pmol: 10 μ 。 [0015] HepG2 cells (purchased from ATCC), cultured in DMEM complete medium (containing 10% fetal bovine serum), plated 6-well plates at a ratio of 150,000 cells/well, and cultured at 37 ° C, 5% CO 2 for 18 h. . Cell transfection was performed using the Lipofectamine 3000 Transfection Kit (Invitrogen) according to the product instructions. Transfected sputum, transfected A375 cells with lOO pmol siPDL1, the ratio of siRNA to liposome was 100 pmol: 10 μ.
[0016] 实施例三定量 PCR检测平 PD-L1基因表达水平 [0016] Example 3 quantitative PCR detection of flat PD-L1 gene expression level
[0017] 提取总 RNA: 使用 QIAGEN RNeasy Mini Kit提取正常和转染 siPDLl的 PD-L1细 胞的总 RNA。 [0017] Total RNA extraction: Total RNA of PD-L1 cells normal and transfected with siPDL1 was extracted using the QIAGEN RNeasy Mini Kit.
[0018] 逆转录： 使用 FastQuant RT Super Mix (天根生化） 进行逆转录。 [0018] Reverse Transcription: Reverse transcription was performed using FastQuant RT Super Mix.
[0019] 定量 PCR: 使用 SYBR Premix Ex Taq (Tli RNaseH Plus) (大连宝生物） [0019] Quantitative PCR: Using SYBR Premix Ex Taq (Tli RNaseH Plus) (Dalian Bao Bio)
进行定量 PCR， 检测， 反应体系为 20 μί， 每个反应加入 1 L cDNA作为模板。 反应程序为： (1)95 °C 30 s, (2)95 °C 5s, (3)60°C 30s, (2)-(3)， 40个循环。 同吋 以 GAPDH为内参， 结果如图 1所示， 可以看到， 转染 siPDLl后的 HepG2细胞， P D-L1基因的 mRNA表达水平与正常 HepG2细胞相比显著下降， 说明本发明的 siPD L1能够高效特异性抑制 PD-L1基因的表达。 Quantitative PCR was carried out, and the reaction system was 20 μί, and 1 L cDNA was added as a template for each reaction. The reaction procedure is: (1) 95 °C 30 s, (2) 95 °C 5s, (3) 60 °C 30s, (2)-(3), 40 cycles. With GAPDH as the internal reference, the results are shown in Figure 1. It can be seen that the expression level of P D-L1 mRNA in HepG2 cells transfected with siPDL1 is significantly lower than that of normal HepG2 cells, indicating that siPD L1 of the present invention It can efficiently and specifically inhibit the expression of the PD-L1 gene.
工业实用性 Industrial applicability
[0020] 本发明提供的 siPDLl具有干扰效率高， 可高效、 特异地抑制 PD-L1基因表达的 优点， 可作为有力工具应用于制备治疗 PD-L1基因表达异常相关疾病的药物。
The siPDL1 provided by the present invention has the advantages of high interference efficiency, high and specific inhibition of PD-L1 gene expression, and can be used as a powerful tool for preparing a medicament for treating a PD-L1 gene expression-related disease.
Claims
[权利要求 1] 一种 RNA干扰片段， 其特征在于， 所述 RNA干扰片段的序列如下: [Claim 1] An RNA interference fragment, wherein the sequence of the RNA interference fragment is as follows:
正义链： 5，- GCCGAAGUCAUCUGGACAA-3' (SEQ ID NO: 1) ： 反义链： 5'- UUGUCCAGAUGACUUCGGC-3' (SEQ ID NO: 2) ' Sense chain: 5,- GCCGAAGUCAUCUGGACAA-3' (SEQ ID NO: 1): antisense strand: 5'- UUGUCCAGAUGACUUCGGC-3' (SEQ ID NO: 2) '
[权利要求 2] 权利要求 1中所述的 RNA干扰片段的应用， [Claim 2] The use of the RNA interference fragment of claim 1
其特征在于制备治疗 PD-L1基因表达异常相关疾病的药物。
It is characterized by the preparation of a medicament for treating a disease associated with abnormal expression of the PD-L1 gene.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/CN2017/089929 WO2019000149A1 (en) | 2017-06-26 | 2017-06-26 | Sirna of human programmed death-ligand 1 gene and use thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/CN2017/089929 WO2019000149A1 (en) | 2017-06-26 | 2017-06-26 | Sirna of human programmed death-ligand 1 gene and use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2019000149A1 true WO2019000149A1 (en) | 2019-01-03 |
Family
ID=64741975
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/CN2017/089929 WO2019000149A1 (en) | 2017-06-26 | 2017-06-26 | Sirna of human programmed death-ligand 1 gene and use thereof |
Country Status (1)
| Country | Link |
|---|---|
| WO (1) | WO2019000149A1 (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007084865A2 (en) * | 2006-01-13 | 2007-07-26 | Sirna Therapeutics, Inc. | RNA INTERFERENCE MEDIATED INHIBITION OF B7-H1 GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
| WO2017040078A1 (en) * | 2015-09-02 | 2017-03-09 | Alnylam Pharmaceuticals, Inc. | PROGRAMMED CELL DEATH 1 LIGAND 1 (PD-L1) iRNA COMPOSITIONS AND METHODS OF USE THEREOF |
-
2017
- 2017-06-26 WO PCT/CN2017/089929 patent/WO2019000149A1/en active Application Filing
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007084865A2 (en) * | 2006-01-13 | 2007-07-26 | Sirna Therapeutics, Inc. | RNA INTERFERENCE MEDIATED INHIBITION OF B7-H1 GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
| WO2017040078A1 (en) * | 2015-09-02 | 2017-03-09 | Alnylam Pharmaceuticals, Inc. | PROGRAMMED CELL DEATH 1 LIGAND 1 (PD-L1) iRNA COMPOSITIONS AND METHODS OF USE THEREOF |
Non-Patent Citations (2)
| Title |
|---|
| HUANG, WENYUE: "Research on Inhibition of B7-H1 Gene Expression in Human Umbilical Cord Mesenchymal Stem Cells by RNAi Technology", CHINA DISSERTATION DATABASE, 8 November 2013 (2013-11-08) * |
| WILLEMIJN HOBO ET AL.: "SiRNA Silencing of PD-L1 and PD-L2 on Dendritic Cells Augments Expansion and Function of Minor Histocompatibility Antigen-specific CD 8+ T Cells", BLOOD. IMMUNOBIOLOGY, vol. 116, no. 22, 25 November 2010 (2010-11-25), pages 4501 - 4510, XP055558438, ISSN: 0171-2985 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2019000146A1 (en) | Sirna of human programmed cell death receptor 1 and use thereof | |
| Guo et al. | C-Myc negatively controls the tumor suppressor PTEN by upregulating miR-26a in glioblastoma multiforme cells | |
| JP6081798B2 (en) | Methods and compositions and miRNA inhibitors and targets for detecting and treating cancers associated with miRNA | |
| JP2010529857A (en) | Oncogenic ALL-1 fusion protein for targeting DROSHA-mediated microRNA processing | |
| TW200908987A (en) | RNA antagonist compounds for the modulation of HER3 | |
| CN113817823A (en) | Long non-coding RNA LETN as tumor marker and treatment target | |
| Li et al. | Long non‑coding RNA PLK1S1 was associated with renal cell carcinoma progression by interacting with microRNA‑653 and altering C‑X‑C chemokine receptor 5 expression | |
| KR102321426B1 (en) | Asymmetric siRNA Inhibiting Expression of Genes Directed to Male Type Depilation | |
| US11013754B2 (en) | Compositions and methods for treating cancer | |
| AU2009302344A1 (en) | Treating Hepatitis C virus infection with over-expression of microRNA-196 | |
| CN106591308A (en) | Human pulmonary carcinoma erlotinib drug tolerance improving shRNA | |
| WO2019000149A1 (en) | Sirna of human programmed death-ligand 1 gene and use thereof | |
| WO2018170766A1 (en) | Sirna of human programmed death ligand 2 gene and application thereof | |
| CN102229928B (en) | Small-interfering RNA (Ribonucleic Acid) of human RBBP6 (Retinoblastoma-binding Proteingene) and application thereof | |
| WO2019000148A1 (en) | Sirna of human abcb6 gene and use thereof | |
| Hope et al. | MicroRNA-139 expression is dispensable for the generation of influenza-specific CD8+ T cell responses | |
| Priyadarshini et al. | Downregulation of ribosomal RNA (rRNA) genes in human head and neck squamous cell carcinoma (HNSCC) cells correlates with rDNA promoter hypermethylation | |
| KR102069945B1 (en) | Methods for inducing tumorigenesis of neural stem cells using EGFRviii expression | |
| CN116803424B (en) | SLC17A5 gene inhibitor and application thereof | |
| US9139829B2 (en) | SiRNA targeting ETS1 and ELK1 and method of using same in the inhibition of CIP2A gene in cancer treatment | |
| US20110117181A1 (en) | Treating hepatitis c virus infection with over-expression of microrna-196 | |
| CN101328199A (en) | SiRNA inhibiting human cell cycle protein A2 expression and use thereof | |
| CN104611333A (en) | SiRNA for reducing human POKEMON gene expression and related application thereof | |
| KR101581721B1 (en) | Compositions supportive for treating drug-resistanced breast cancer containing miR-500a-3p and sensitizing method for anticancer reagent in drug-resistanced breast cancer patient | |
| CN116179552A (en) | siRNA for inhibiting expression of human FAM86B1 gene and FAM86B1 low-expression cell line |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 17916004 Country of ref document: EP Kind code of ref document: A1 |
|
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| 122 | Ep: pct application non-entry in european phase |
Ref document number: 17916004 Country of ref document: EP Kind code of ref document: A1 |
|
| 122 | Ep: pct application non-entry in european phase |
Ref document number: 17916004 Country of ref document: EP Kind code of ref document: A1 |